Login to Your Account



Another twist in eteplirsen saga gives Sarepta more rope, but to what end?

By Marie Powers
News Editor

Tuesday, June 7, 2016

In a brief statement released following Monday's market close, Sarepta Therapeutics Inc. revealed that the FDA requested additional dystrophin data as part of its ongoing review of the NDA for DMD candidate, eteplirsen.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription